Publications:  Dr Tatjana Crnogorac-Jurcevic

Debernardi S, O'Brien H, Algahmdi AS, Malats N, Stewart GD, Pljesa-Ercegovac M, Costello E, Greenhalf W et al.(2020). A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. PLoS Medicine vol. 17, (12)

Blyuss O, Crnogorac-Jurcevic T(2020). Response to the comment on "Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients". Br J Cancer vol. 123, (9)

Daulton E, Wicaksono AN, Tiele A, Kocher HM, Debernardi S, Crnogorac-Jurcevic T, Covington JA(2020). Volatile organic compounds (VOCs) for the non-invasive detection of pancreatic cancer from urine. Talanta vol. 221,

Camara R, Ogbeni D, Gerstmann L, Ostovar M, Hurer E, Scott M, Mahmoud NG, Radon T et al.(2020). Discovery of novel small molecule inhibitors of S100P with in vitro anti-metastatic effects on pancreatic cancer cells. European Journal of Medicinal Chemistry112621-112621.

Molina-Montes E, Van Hoogstraten L, Gomez-Rubio P, Löhr M, Sharp L, Molero X, Márquez M, Michalski CW et al.(2020). Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29, (5) 1009-1018.

Schilling K, Larner F, Saad A, Roberts R, Kocher HM, Blyuss O, Halliday AN, Crnogorac-Jurcevic T(2020). Urine metallomics signature as an indicator of pancreatic cancer. Metallomics: integrated biometal science

Blyuss O, Zaikin A, Cherepanova V, Munblit D, Kiseleva EM, Prytomanova OM, Duffy SW, Crnogorac-Jurcevic T(2020). Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients. British Journal of Cancer vol. 122, (5) 692-696.

Molina-Montes E, Coscia C, Gómez-Rubio P, Fernández A, Boenink R, Rava M, Márquez M, Molero X et al.(2020). Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Gut

Barry S, Carlsen E, Marques P, Stiles CE, Gadaleta E, Berney DM, Roncaroli F, Chelala C et al.(2019). Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. Oncogene vol. 38, (27) 5381-5395.

Crnogorac-Jurcevic T, Radon T, Shah S, Weeks M, Foster J, Sosabowski J, Dumartin L(2019). AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting. Oncotarget

Goulart MR, Watt J, Siddique I, Lawor R, Dowe T, Bhattacharya S, Crnogorac-Jurcevic T, Allavena P et al. (2019). Abstract 4892: Pentraxin 3: A stromal derived diagnostic biomarker for pancreatic ductal adenocarcinoma. 4892-4892.

Blyuss O, Duffy S, Crnogorac-Jurcevic T (2019). Development of a biomarker panel risk score, PancRISK, for early detection of pancreatic cancer.

Montes EM, Molero X, Fernández A, Estudillo L, Carrato A, Rodriguez J, Ilzarbe L, Farré A et al. (2019). Prognostic value of reliably assessed diabetes mellitus type 2 in pancreatic cancer. Pancreatology. vol. 19, s3-s4.

Alrawashdeh W, Jones R, Dumartin L, Radon TP, Cutillas PR, Feakins RM, Dmitrovic B, Demir IE et al.(2019). Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling. Mol Oncol vol. 13, (5) 1075-1091.

Gomez-Rubio P, Piñero J, Molina-Montes E, Gutiérrez-Sacristán A, Marquez M, Rava M, Michalski CW, Farré A et al.(2019). Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case–control approaches. International Journal of Cancer vol. 144, (7) 1540-1549.

Ntala C, Debernardi S, Feakins RM, Crnogorac-Jurcevic T(2018). Demographic, clinical, and pathological features of early onset pancreatic cancer patients. BMC Gastroenterol vol. 18, (1)

Molina-Montes E, Gomez-Rubio P, Márquez M, Rava M, Löhr M, Michalski CW, Molero X, Farré A et al.(2018). Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. International Journal of Epidemiology vol. 47, (2) 473-483.

Lee MH, Thomas JL, Liao CL, Jurcevic S, Crnogorac-Jurcevic T, Lin HY(2018). Epitope recognition of peptide-imprinted polymers for Regenerating protein 1 (REG1). Separation and Purification Technology vol. 192, 213-219.

Wang J, Dumartin L, Mafficini A, Ulug P, Sangaralingam A, Alamiry NA, Radon TP, Salvia R et al.(2017). Splice variants as novel targets in pancreatic ductal adenocarcinoma. Scientific Reports vol. 7, (1)

CRNOGORAC-JURCEVIC T(2017). Non-invasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine. Gastroenterology

Barry S, Solomou A, Vignola L, Collier D, Carlsen E, Gadaleta E, Berney DM, Chelala C et al.(2017). A comprehensive analysis of the AIP mutation positive pituitary tumour microenvironment: role of stromal cells and the pro-inflammatory cytokine network. Endocrine Abstracts

Marzec J, Dayem Ullah AZ, Pirrò S, Gadaleta E, Crnogorac-Jurcevic T, Lemoine NR, Kocher HM, Chelala C(2017). The Pancreatic Expression Database: 2018 update. Nucleic Acids Res vol. 46, (D1) D1107-D1110.

Gomez-Rubio P, Rosato V, Márquez M, Bosetti C, Molina-Montes E, Rava M, Piñero J, Michalski CW et al.(2017). A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. Ann Oncol vol. 28, (7) 1618-1624.

Lee M-H, Thomas JL, Liao C-L, Jurcevic S, Crnogorac-Jurcevic T, Lin H-Y(2017). Polymers imprinted with three REG1B peptides for electrochemical determination of Regenerating Protein 1B, a urinary biomarker for pancreatic ductal adenocarcinoma. Microchimica Acta vol. 184, (6) 1773-1780.

Gomez-Rubio P, Zock J-P, Rava M, Marquez M, Sharp L, Hidalgo M, Carrato A, Ilzarbe L et al.(2017). Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut vol. 66, (2) 314-322.

CRNOGORAC-JURCEVIC T, Dumartin L, Alrawashdeh W, Trabulo SM, Radon TP, Steiger K, Feakins RM, di Magliano MP et al.(2016). ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. Oncogene

Cutillas PR, Crnogorac-Jurcevic T(2016). Application of Proteomics in Cancer Biomarker Discovery: GeLC-MS/MS. Methods Mol Biol vol. 1381, 201-209.

Prica F, Radon T, Cheng Y, Crnogorac-Jurcevic T(2016). The life and works of S100P - from conception to can. American Journal of Cancer Research vol. 6, (2) 562-576.

Radon TP, Massat NJ, Jones R, Alrawashdeh W, Dumartin L, Ennis D, Duffy SW, Kocher HM et al.(2015). Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma. Clinical Cancer Research vol. 21, (15) 3512-3521.

Watt J, Siddique I, Dowe T, Crnogorac-Jurcevic T, Bhattacharya S, Allavena P, Kocher HM (2015). Abstract A56: The role of Pentraxin 3 (PTX3) in pancreatic ductal adenocarcinoma. a56-a56.

Wong PP, Demircioglu F, Ghazaly E, Alrawashdeh W, Stratford MRL, Scudamore CL, Cereser B, Crnogorac-Jurcevic T et al.(2015). Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell vol. 27, (1) 123-137.

Wong P-P, Demircioglu F, Ghazaly E, Alrawashdeh W, Stratford M, Scudamore C, Cereser B, Crnogorac-Jurcevic T et al. (2015). NOVEL DUAL-ACTION COMBINATION THERAPY ENHANCES ANGIOGENESIS WHILST REDUCING TUMOR GROWTH AND SPREAD. JOURNAL OF VASCULAR RESEARCH. vol. 52, 6-6.

Debernardi S, Massat NJ, Radon TP, Sangaralingam A, Banissi A, Ennis DP, Dowe T, Chelala C et al.(2015). Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. American Journal of Cancer Research vol. 5, (11) 3455-3466.

Haider S, Wang J, Nagano A, Desai A, Arumugam P, Dumartin L, Fitzgibbon J, Hagemann T et al.(2014). A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Medicine vol. 6, (12)

Watt J, Siddiqui I, Radon T, Dowe T, Crnogorac-Jurcevic T, Allavena P, Kocher H (2014). Pentraxin3 Is a Stromal Biomarker in Pancreatic Ductal Adenocarcinoma. GASTROENTEROLOGY. vol. 146, S276-S276.

Watt J, Siddique I, Dowe T, Crnogorac-Jurcevic T, Allavena P, Kocher H(2014). Role of PTX3 in pancreatic cancer. The Lancet vol. 383,

Dayem Ullah AZ, Cutts RJ, Ghetia M, Gadaleta E, Hahn SA, Crnogorac-Jurcevic T, Lemoine NR, Chelala C(2014). The pancreatic expression database: recent extensions and updates. Nucleic Acids Res vol. 42, (Database issue) D944-D949.

Barry S, Chelala C, Lines K, Sunamura M, Wang A, Marelli-Berg FM, Brennan C, Lemoine NR et al.(2013). S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells. Clin Exp Metastasis vol. 30, (3) 251-264.

Crnogorac-Jurcevic T, Chelala C, Barry S, Harada T, Bhakta V, Lattimore S, Jurcevic S, Bronner M et al.(2013). Molecular analysis of precursor lesions in familial pancreatic cancer. PLoS One vol. 8, (1)

Alkhamis T, Barbic J, Crnogorac-Jurcevic T, Greenlaw RE, Peakman M, Jurcevic S(2012). Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice. Clin Exp Immunol vol. 170, (2) 139-148.

Alrawashdeh W, Jones R, Cutillas P, Wijesuriya N, Crnogorac-Jurcevic T(2012). Proteomic Analysis of Perineural Invasion in Pancreatic Adenocarcinoma Reveals Up-Regulation of Neurosecretory Protein VGF in Invaded Nerves. PANCREAS vol. 41, (8) 1346-1346.

CRNOGORAC-JURCEVIC T, LINES KE (2012). S100PBP. Atlas of Genetics and Cytogenetics in Oncology and Haematology

Naidoo K, Jones R, Dmitrovic B, Wijesuriya N, Kocher H, Hart IR, Crnogorac-Jurcevic T(2012). Proteome of formalin-fixed paraffin-embedded pancreatic ductal adenocarcinoma and lymph node metastases. J Pathol vol. 226, (5) 756-763.

Lines KE, Chelala C, Dmitrovic B, Wijesuriya N, Kocher HM, Marshall JF, Crnogorac-Jurcevic T(2012). S100P-binding protein, S100PBP, mediates adhesion through regulation of cathepsin Z in pancreatic cancer cells. Am J Pathol vol. 180, (4) 1485-1494.

Dumartin L, Whiteman HJ, Weeks ME, Hariharan D, Dmitrovic B, Iacobuzio-Donahue CA, Brentnall TA, Bronner MP et al.(2011). AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res vol. 71, (22) 7091-7102.

Gadaleta E, Cutts RJ, Kelly GP, Crnogorac-Jurcevic T, Kocher HM, Lemoine NR, Chelala C(2011). A global insight into a cancer transcriptional space using pancreatic data: importance, findings and flaws. Nucleic Acids Res vol. 39, (18) 7900-7907.

Tolhurst RS, Thomas RS, Kyle FJ, Patel H, Periyasamy M, Photiou A, Thiruchelvam PTR, Lai C-F et al.(2011). Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth. Breast Cancer Res Treat vol. 128, (2) 357-368.

Lines KE, Audi N, Chelala C, Wijesuriya N, Kocher H, Hurst H, Crnogorac-Jurcevic T(2011). Abstract 1537: Role of S100PBP in pancreatic adenocarcinoma. 1537-1537.

Crnogorac-Jurcevic T, Alrawashdeh W(2011). Biomarker discovery in biological fluids. Sample Preparation in Biological Mass Spectrometry, Editors: Ivanov, AR, Lazarev, A, Springer

Cutts RJ, Gadaleta E, Hahn SA, Crnogorac-Jurcevic T, Lemoine NR, Chelala C(2011). The Pancreatic Expression database: 2011 update. Nucleic Acids Res vol. 39, (Database issue) D1023-D1028.

Dumartin L, Whiteman HJ, Weeks ME, Timms JF, Brentnall TA, Bronner MP, Brennan C, Lemoine NR et al.(2010). AGR2 Regulates the Invasion of Pancreatic Cancer Cells Through Cathepsins B and D. PANCREAS vol. 39, (8) 1318-1319.

Jiang G, Cao F, Ren G, Gao D, Bhakta V, Zhang Y, Cao H, Dong Z et al.(2010). PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. Gut vol. 59, (11) 1535-1544.

Schröder C, Jacob A, Tonack S, Radon TP, Sill M, Zucknick M, Rüffer S, Costello E et al.(2010). Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Mol Cell Proteomics vol. 9, (6) 1271-1280.

Hariharan D, Weeks ME, Crnogorac-Jurcevic T(2010). Application of proteomics in cancer gene profiling: two-dimensional difference in gel electrophoresis (2D-DIGE). Methods Mol Biol vol. 576, 197-211.

Chelala C, Lemoine NR, Hahn SA, Crnogorac-Jurcevic T(2009). A web-based platform for mining pancreatic expression datasets. Pancreatology vol. 9, (4) 340-343.

Harada T, Chelala C, Crnogorac-Jurcevic T, Lemoine NR(2009). Genome-wide analysis of pancreatic cancer using microarray-based techniques. Pancreatology vol. 9, (1-2) 13-24.

Weeks ME, Hariharan D, Petronijevic L, Radon TR, Whiteman HJ, Kocher HM, Timms JF, Lemoine NR et al.(2008). Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma. PROTEOM CLIN APPL vol. 2, (7-8) 1047-1057.

Barry S, Crnogorac-Jurcevic T (2008). S100P.

Hariharan D, Crnogorac-Jurcevic T(2008). Expression profiling of chronic pancreatitis. Pancreatitis Research Advances, Nova Publishers Ltd (New York, USA),

Chelala C, Hahn SA, Whiteman HJ, Barry S, Hariharan D, Radon TP, Lemoine NR, Crnogorac-Jurcevic T(2007). Pancreatic Expression database: a generic model for the organization, integration and mining of complex cancer datasets. BMC Genomics vol. 8,

Whiteman HJ, Weeks ME, Dowen SE, Barry S, Timms JF, Lemoine NR, Crnogorac-Jurcevic T(2007). The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Cancer Res vol. 67, (18) 8633-8642.

Sheikh A, Vimalachandran D, Thompson CC, Jenkins RE, Nedjadi T, Shekouh A, Campbell F, Dodson A et al.(2007). The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer. Proteomics vol. 11, (4) 1929-1940.

Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher HM, Harada T, Zhu M, Kalthoff H et al.(2007). Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene vol. 26, (14) 2082-2094.

Neesse A, Gangeswaran R, Luettges J, Feakins R, Weeks ME, Lemoine NR, Crnogorac-Jurcevic T(2007). Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells. Oncogene vol. 26, (11) 1533-1545.

Thompson CC, Ashcroft FJ, Patel S, Saraga G, Vimalachandran D, Prime W, Campbell F, Dodson A et al.(2007). Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut vol. 56, (1) 95-106.

Pogue-Geile KL, Chen R, Bronner MP, Crnogorac-Jurcevic T, Moyes KW, Dowen S, Otey CA, Crispin DA et al.(2006). Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med vol. 3, (12)

Neesse A, Gangeswaran R, Luettges J, Feakins R, Weeks ME, Lemoine NR, Crnogorac-Jurcevic T(2006). Sperm associated antigen 1 (spag1) is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells. PANCREAS vol. 33, (4) 485-486.

Capurso G, Lattimore S, Crnogorac-Jurcevic T, Panzuto F, Milione M, Bhakta V, Campanini N, Swift SM et al.(2006). Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer vol. 13, (2) 541-558.

Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W et al.(2005). Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology vol. 129, (5) 1454-1463.

Vimalachandran D, Greenhalf W, Thompson C, Lüttges J, Prime W, Campbell F, Dodson A, Watson R et al.(2005). High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res vol. 65, (8) 3218-3225.

Akada M, Crnogorac-Jurcevic T, Lattimore S, Mahon P, Lopes R, Sunamura M, Matsuno S, Lemoine NR(2005). Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res vol. 11, (8) 3094-3101.

Missiaglia E, Donadelli M, Palmieri M, Crnogorac-Jurcevic T, Scarpa A, Lemoine NR(2005). Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene vol. 24, (1) 199-211.

Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, Hansen M, Eloranta JJ, Bhakta V, Brentnall TA, Lüttges J et al.(2005). Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol vol. 166, (1) 81-92.

Crnogorac-Jurcevic T(2005). Expression profiling in pancreatic cancer using microarray technology. Exocrine pancreas cancer, Editors: Gress, TM, Neoptolemos, JP, Lemoine, NR, Real, FX et al., Solvay Pharmaceuticals

Capurso G, Crnogorac-Jurcevic T, Milione M, Panzuto F, Campanini N, Dowen SE, Di Florio A, Sette C et al.(2005). Peanut-like 1 (septin 5) gene expression in normal and neoplastic human endocrine pancreas. Neuroendocrinology vol. 81, (5) 311-321.

Crnogorac-Jurcevic T, Poulsom R, Lemoine NR(2005). The molecular pathology of cancer. Introduction to the Cellular & Molecular Biology of Cancer, Editors: Knowles, M, Selby, P, Edition. 4th, Oxford University Press (Oxford),

Missiaglia E, Blaveri E, Terris B, Wang Y-H, Costello E, Neoptolemos JP, Crnogorac-Jurcevic T, Lemoine NR(2004). Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer vol. 112, (1) 100-112.

Shekouh AR, Thompson CC, Prime W, Campbell F, Hamlett J, Herrington CS, Lemoine NR, Crnogorac-Jurcevic T et al.(2003). Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics vol. 3, (10) 1988-2001.

Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, Gangeswaran R, Jones M, Terris B, Costello E, Neoptolemos JP et al.(2003). Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol vol. 201, (1) 63-74.

Zhu G, Reynolds L, Crnogorac-Jurcevic T, Gillett CE, Dublin EA, Marshall JF, Barnes D, D'Arrigo C et al.(2003). Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer. Oncogene vol. 22, (24) 3742-3748.

VAN TRAPPEN P(2003). Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer. Oncogene vol. 22, 3742-3748.

Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A et al.(2002). Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene vol. 21, (29) 4587-4594.

Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine NR(2002). Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol vol. 160, (5) 1745-1754.

Fischer C, Bouneau L, Ozouf-Costaz C, Crnogorac-Jurcevic T, Weissenbach J, Bernot A(2002). Conservation of the T-cell receptor alpha/delta linkage in the teleost fish Tetraodon nigroviridis. GENOMICS vol. 79, (2) 241-248.

Crnogorac-Jurcevic T, Nielsen TO, Lemoine NR(2002). RT-PCR from laser-capture microdissected samples. Methods Mol Biol vol. 193, 197-204.

Crnogorac-Jurcevic T, Efthimiou E, Capelli P, Blaveri E, Baron A, Terris B, Jones M, Tyson K et al.(2001). Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene vol. 20, (50) 7437-7446.

Efthimiou E, Crnogorac-Jurcevic T, Lemoine NR, Brentnall TA(2001). Inherited predisposition to pancreatic cancer. Gut vol. 48, (2) 143-147.

Efthimiou E, Crnogorac-Jurcevic T, Lemoine NR(2001). Pancreatic cancer genetics. Pancreatology vol. 1, (6) 571-575.

Lemoine NR, Sirivatanauksorn V, CRNOGORAC-JURCEVIC T(2000). Molecular profile of pancreatic cancer. Molecular Pathogenesis of Pancreatic Cancer, vol. 41, IOS Press